BioAge Labs, Inc. (BIOA) - Dilution Analysis

10-Q filing | 42.5M shares outstanding

10-K filing | 44.4M shares outstanding

8-K filing: BioAge Labs, Inc. entered into an underwriting agreement to issue and sell 5,897,435 shares of common stock in a public offering at a price of $19.50 per share, with an option for the underwriters to purchase an additional 884,615 shares. ($115.0M proceeds)

10-Q filing | 35.9M shares outstanding

S-3/A filing: BioAge, Inc. is offering 2,227,124 shares of common stock by the selling stockholder.

S-3/A filing: This S-3/A filing from BioAge, Inc. describes a mixed shelf offering of common stock, preferred stock, debt securities, warrants, subscription rights, and units, with a total offering amount of up to $250 million.

S-3 filing: This prospectus relates to the proposed resale or other disposition from time to time, in one or more offerings, by the selling stockholder identified in this prospectus of up to an aggregate of 2,227,124 shares of our common stock, par value $0.00001 per share.

10-Q filing | 35.9M shares outstanding

10-Q filing | 35.9M shares outstanding

10-K filing | 35.9M shares outstanding

10-Q filing | 35.8M shares outstanding

S-1/A filing: This S-1/A filing describes an initial public offering of 10,500,000 shares of common stock. It also mentions a concurrent private placement of common stock to Sofinnova Venture Partners.

S-1/A filing: This is an S-1/A filing for the initial public offering of BioAge Labs, Inc., offering 7,500,000 shares of common stock with an estimated price range of $17.00 to $19.00 per share, and includes shares of Series D Preferred Stock purchased by Andreessen Horowitz, Cormorant, and Longitude Venture Partners IV, L.P.

S-1 filing: This S-1 filing relates to an offering of Series D-1 Preferred Stock by entities affiliated with Andreessen Horowitz, Cormorant, Longitude Venture Partners IV, L.P., Sofinnova Venture Partners XI, L.P., RA Capital, Khosla Ventures, and Horsley Bridge.